Claritev (NYSE:CTEV) Releases Earnings Results, Beats Estimates By $0.04 EPS

Claritev (NYSE:CTEV) issued its quarterly earnings data on Monday. The company reported ($3.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.68) by $0.04, Zacks reports.

Here are the key takeaways from Claritev’s conference call:

• Third-quarter revenue rose 9.1% year over year to $268.3 million and Adjusted EBITDA increased 4.4% to $162 million, exceeding expectations. Claritev raised its 2026 revenue, Adjusted EBITDA, and free cash flow guidance.
• Bookings reached $27 million in Q3 and topped $100 million year to date; the company now expects $115 million–$125 million for 2026, up 70%–90% from 2025. More than half of year-to-date bookings came from outside its core payer market, supporting management’s diversification strategy.
• Claims Intelligence grew 17.1%, with NSA dispute initiations up 75% year over year; management expects NSA activity to remain a tailwind. The company also said it expects at least $1.1 billion in revenue in 2027, a year ahead of its prior target.
• Payment & Revenue Integrity remained below plan as clients shifted from legacy clinical negotiations, more than offsetting growth in newer offerings. Management expects the segment to return to growth in 2027, but noted that bookings typically take time to convert to revenue.
• Claritev reported a $25.8 million Q3 free cash flow outflow and ended the quarter with $10.1 million of unrestricted cash, $95 million drawn on its revolver, and net leverage of 7.7x. Management expects a strong Q4 cash-flow rebound and reaffirmed its commitment to deleveraging.

Claritev Trading Up 0.2%

NYSE:CTEV opened at $22.75 on Monday. The company has a market capitalization of $385.54 million, a P/E ratio of -1.34 and a beta of 1.05. Claritev has a 12 month low of $11.50 and a 12 month high of $73.68. The firm has a fifty day simple moving average of $27.44 and a 200-day simple moving average of $25.51.

Analyst Upgrades and Downgrades

CTEV has been the topic of several recent research reports. Wells Fargo & Company increased their target price on Claritev from $22.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 12th. Barclays reiterated an “overweight” rating and issued a $40.00 price target (up from $28.00) on shares of Claritev in a report on Thursday, August 20th. Piper Sandler reissued an “overweight” rating and issued a $73.00 price target on shares of Claritev in a research report on Wednesday, August 12th. Citigroup reaffirmed a “buy” rating and set a $45.00 price objective (up from $40.00) on shares of Claritev in a research report on Monday, August 10th. Finally, Canaccord Genuity Group boosted their target price on shares of Claritev from $37.00 to $43.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.83.

Insider Transactions at Claritev

In related news, CFO Douglas Garis sold 9,025 shares of the firm’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $30.59, for a total value of $276,074.75. Following the completion of the transaction, the chief financial officer owned 185,416 shares in the company, valued at $5,671,875.44. This trade represents a 4.64% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Travis Dalton purchased 4,500 shares of the stock in a transaction on Thursday, August 27th. The shares were purchased at an average cost of $38.81 per share, with a total value of $174,645.00. Following the transaction, the chief executive officer owned 50,372 shares in the company, valued at $1,954,937.32. This trade represents a 9.81% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders bought 77,284 shares of company stock valued at $1,927,655 and sold 23,687 shares valued at $769,078. Company insiders own 7.40% of the company’s stock.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.